Lenvatinib: New Kid on the Block 2015/05/08 OncLiveTV
(00:48-) I remember one of the first patients that I treated with this trial was a gentleman that came in with very large tumors in his neck we enrolled him in the clinical trial and he started taking the medication he called us about a week later and said Dr. Taylor you’re not gonna believe this but I feel like the tumors are already getting substantially smaller and they’re softer.
レンバチニブの臨床試験に関する論文
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date. J Hepatocell Carcinoma. 2019; 6: 31–39. PMC6362912 the Phase III REFLECT trial showed that another multikinase inhibitor, namely, lenvatinib, was non-inferior to sorafenib in terms of overall survival (OS).
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. THE LANCET VOLUME 391, ISSUE 10126, P1163-1173, MARCH 24, 2018 (HTML)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer February 12, 2015 N Engl J Med 2015; 372:621-630 (HTML フルテキスト閲覧可能) Phase 3, randomized, double-blind, multicenter study involving patients with progressive thyroid cancer that was refractory to iodine-131. Funded by Eisai; SELECT ClinicalTrials.gov number, NCT01321554. opens in new tab.
Developing Physician-Scientists Carpe Diem Nancy J. Brown Originally published30 Aug 2018 https://doi.org/10.1161/CIRCRESAHA.118.313473 Circulation Research. 2018;123:645–647
Becoming a Physician–Scientist A View Looking Up From Base Camp Ganetzky, Rebecca D. MD Academic Medicine: October 2017 – Volume 92 – Issue 10 – p 1373–1374 PDF
Consent Form for Case Reports 症例報告に関する同意書
Erlanger Health System/University of Tennessee College of Medicine アランジャー・ヘルス・システム／テネシー大学医学部
You are being asked to consider allowing Dr. (insert name) to use information about your (insert condition/disease/experience) to write what is called a case report. Case reports are typically used to share new unique information experienced by one patient during his/her clinical care that may be useful for other physicians and members of a health care team. A case report may be published (in print and/or via internet dissemination) for others to read, and/or presented at a conference. This form explains the purpose of this case report. Please read this form carefully and take your time to make your decision and ask any questions that you may have. あなたは、博士（名前を入れてください）があなたの（症状／病気／経験を入れてください）に関する情報を使用して、ケースレポートと呼ばれるものを書くことを許可することを検討するよう求められています。 症例報告は、通常、ある患者が臨床治療中に経験した、他の医師や医療チームのメンバーにとって有用と思われる新しい独自の情報を共有するために使用されます。 症例報告は、他の人が読めるように（印刷物やインターネットを通じて）出版されることもあれば、学会で発表されることもあります。 この書式は、この症例報告の目的を説明するものです。 このフォームを注意深く読み、時間をかけて決断し、疑問点を質問してください。
Dr. (insert name) is obligated to protect your privacy and not disclose your personal information (information about you and your health that identifies you as an individual e.g. name, date of birth, medical record number). When the case report is published or presented, your identity will not be disclosed.
Dr. (名前を入れてください)は、あなたのプライバシーを保護する義務があり、あなたの個人情報（あなたやあなたの健康に関する情報であって、個人として特定できるもの 例：名前、生年月日、医療記録番号）を開示することはありません。症例報告書が出版または発表される場合、あなたの身元が明らかになることはありません。
下の例は、患者さんが提出する同意書の部分のみ。
CASE REPORT PATIENT INFORMED CONSENT (https://www.heel.com/media/downloads_pdf/heel_com_1/heel_com_clinical_case_award/hhr2018_casereportpic_en.pdf)
